contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


initiator-pharmas-ip2015-obtains-the-international-nonproprietary-name-pudafensine

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Initiator Pharma is a biotechnology company developing drug candidates for diseases of the central and peripheral nervous system. The company's main business focus is on the development of drug candidates used in the treatment of erectile dysfunction in men. Initiator Pharma was founded through a spin-off from the company Saniona and is headquartered in Denmark.

Initiator Pharma

Initiator Pharma A/S, a clinical-stage biotech company, today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) pudafensine as the official...

<div class="mfn-preamble"><p><strong>Initiator Pharma A/S, a clinical-stage biotech company, today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) pudafensine as the official generic name for the company's patented candidate drug IP2015, which is in clinical development in erectile dysfunction and neuropathic pain.</strong></p></div><div class="mfn-body"><p>”We are pleased that our generic name application now is accepted and approved by the WHO. That we are now able to use the generic name for our drug candidate is a clear validation of the project and an important step on the way to a product. From now on, we will use pudafensine in all communication regarding the drug candidate,” says Claus Elsborg Olesen, CEO at Initiator Pharma.</p><p>Pudafensine (formerly IP2015 (7-[(Exo-8-azabicyclo[3.2.1]octan-3-yl)oxy]-3-methoxy-chromen-2-one)), Initiator Pharma's most advanced candidate drug, is in clinical development for both organic erectile dysfunction and neuropathic pain. Within the indication erectile dysfunction, a multi-center phase IIb study is currently being conducted together with MAC Clinical Research in 120 otherwise healthy organic Erectile dysfunction patients. Dosing of all patients in the phase IIb study is expected to be completed in the first half of 2023.</p><p>A recently developed solid dosage form of pudafensine is undergoing a Phase I pharmacokinetic study in healthy subjects, this will enable bridging of all previous data sets to all future clinical studies on pudafensine.</p></div><div class="mfn-footer mfn-contacts mfn-8e6161468890"><p><strong class="mfn-heading-1">For additional information about Initiator Pharma, please contact:</strong></p><hr><p>Claus Elsborg Olesen, CEO<br>Telephone: +45 6126 0035<br>E-mail:&nbsp;<a rel="noopener" href="mailto:ceo@initiatorpharma.com">ceo@initiatorpharma.com</a></p></div><div class="mfn-footer mfn-about mfn-cdb0015b163c"><p><strong class="mfn-heading-1">About Initiator Pharma</strong></p><hr><p>Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – IP2015 and IP2018 – and two preclinical assets. The company is currently conducting a Phase 2b trial with IP2015 in erectile dysfunction of organic origin, and successfully completed a Phase 1 proof of principle trial in neuropathic pain in 2022. With IP2018 the company is conducting a Phase 2a trial for the treatment of erectile dysfunction of psychogenic origin.<br>&nbsp;<br>Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit <a rel="noopener" href="http://www.initiatorpharma.com.">www.initiatorpharma.com.</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/6c822db4-0912-4e89-8a99-12421b07bb2f/initiator-pharmas-ip2015-obtains-the-international-nonproprietary-name-pudafensine.pdf" class="mfn-generated mfn-primary">Initiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine</a></p></div>

Initiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine